- May 9, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Arzerra
(United States) [Available] ,Kesimpta
(United States) [Available]Synonyms :
Ofatumumabum, HuMax-CD20
Class :
Class: antineoplastic agents Subclass: anti-CD20 antibody
Dosage Forms & Strengths:
Solution for injection
20 mg per ml
100 mg per 5 ml in a vial
1000 mg per 50 ml in a vial
chronic lymphocytic leukemia (Cll)
Previously untreated
Cycle 1: 300 mg intravenously on 1st day followed by 1000 mg 1 week later 8th day
Next 28-day cycles: 1,000 mg on 1st day for minimum 3-12 cycles until a best response is achieved
Relapsed CLL
ofatumumab is indicated in combination with cyclophosphamide and fludarabine for relapsed CLL
300 mg intravenously as 1st dose followed by 2nd dose a week later
2nd dose: 1000 mg intravenously, then
3rd dose: 1000 mg on 1st day of a subsequent 28-day cycle up to 6 cycles
Extended treatment
1st dose: 300 mg intravenously on 1st day, followed by a week later
2nd dose: 1000 mg for a week on 8th day, continued for 7 days and then
3rd dose: 1000 mg intravenously and then every 8th week for 2 years
Refractory CLL
1st dose: 300 mg intravenously, followed by the next dose a week later
2nd to 8th dose: 2000 mg intravenously every week for 7 doses
After 4 weeks: 9th to 12th dose: 4 doses of 2000 mg intravenously every 4 weeks
The total regimen contains 12 doses
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
in combination with ofatumumab, abciximab increases the risk of adverse events
in combination with ofatumumab, adalimumab increases the risk of adverse events
In combination with ofatumumab, aducanumab increases the risk of adverse events
in combination with ofatumumab, alemtuzumab increases the risk of adverse events.
in combination with ofatumumab, alirocumab increases the risk of adverse events
in combination with ofatumumab, amivantamab increases the risk of adverse events
in combination with ofatumumab, anifrolumab increases the risk of adverse events.
in combination with ofatumumab, the anthrax vaccine increases the risk of adverse events.
in combination with ofatumumab, asfotase alpha increases the risk of adverse events
in combination with ofatumumab, atezolizumab increases the risk of adverse events
in combination with ofatumumab, bamlanivimab increases the risk of adverse events.
in combination with ofatumumab, basiliximab increases the risk of adverse events
in combination with ofatumumab, bebtelovimab increases the risk of adverse events
in combination with ofatumumab, belimumab increases the risk of adverse events.
in combination with ofatumumab, bezlotoxumab increases the risk of adverse events.
in combination with ofatumumab, bimekizumab increases the risk of adverse events.
in combination with ofatumumab, burosumab increases the risk of adverse events.
in combination with ofatumumab, canakinumab increases the risk of adverse events.
in combination with ofatumumab, caplacizumab increases the risk of adverse events.
in combination with ofatumumab, cemiplimab increases the risk of adverse events.
in combination with ofatumumab, cetuximab increases the risk of adverse events.
in combination with ofatumumab, cilgavimab increases the risk of adverse events.
in combination with ofatumumab, denosumab increases the risk of adverse events.
in combination with ofatumumab, dinutuximab increases the risk of adverse events.
in combination with ofatumumab, dostarlimab increases the risk of adverse events.
in combination with ofatumumab, erythropoietin increases the risk of thrombosis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis
in combination with ofatumumab, fanolesomab increases the risk of adverse events
in combination with ofatumumab, fremanuzumab increases the risk of adverse events
in combination with ofatumumab, galcanezumab increases the risk of adverse events
in combination with ofatumumab, golimumab increases the risk of adverse events
in combination with ofatumumab, guselkumab increases the risk of adverse events
in combination with ofatumumab, IgG increases the risk of adverse events
in combination with ofatumumab, ibalizumab increases the risk of adverse events
in combination with ofatumumab, imlifidase decreases its therapeutic efficacy
in combination with ofatumumab, inebilizumab increases the risk of adverse events
in combination with ofatumumab, infliximab increases the risk of adverse events
in combination with ofatumumab, inotuzumab ozogamicin increases the risk of adverse events
in combination with ofatumumab, isatuximab increases the risk of adverse events
in combination with ofatumumab, isatuximab increases the risk of adverse events
in combination with ofatumumab, lanadelumab increases the risk of adverse events
in combination with ofatumumab, loncastuximab tesirine increases the risk of adverse events
in combination with ofatumumab, maftivimab increases the risk of adverse events
in combination with ofatumumab, mepolizumab increases the risk of adverse events
in combination with ofatumumab, mogamulizumab increases the risk of adverse events
in combination with ofatumumab, muromonab increases the risk of adverse events
in combination with ofatumumab, natalizumab increases the risk of adverse events
in combination with ofatumumab, necitumumab increases the risk of adverse events
in combination with ofatumumab, nivolumab increases the risk of adverse events
in combination with ofatumumab, obiltoxaximab increases the risk of adverse events
in combination with ofatumumab, obinutuzumab increases the risk of adverse events
in combination with ofatumumab, ocrelizumab increases the risk of adverse events
in combination with ofatumumab, o
